Discovery Laboratories has submitted an IND to the FDA to initiate its Phase II clinical program for Aerosurf. The FDA has confirmed receipt of the IND and has indicated that, unless otherwise notified during its review, the company may initiate the program after a 30-day period. Discovery Labs may begin patient enrollment could in 4Q13. Aerosurf is a novel investigational drug-device combination product being developed to deliver Discovery Labs’ KL4 surfactant in aerosolized form to prem...